June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

April 27, 2017April 27, 2017

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

News

Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a list price of $3,500 per month, Valeant Pharmaceuticals announced. The announcement ... Read more

April 20, 2017April 20, 2017

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata

News

XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, says XTRAC’s manufacturer, Strata Skin Sciences of Horsham, Pa. The ... Read more

April 18, 2017April 18, 2017

National Psoriasis Foundation Grants Seal of Recognition to MetaDerm Heal & Prevent Psoriasis Cream

News

The National Psoriasis Foundation (NPF) has given its Seal of Recognition to MetaDerm Heal & Prevent Cream, a therapeutic botanical cream for psoriasis made by Haus Bioceuticals. MetaDerm — one of the first botanical-based therapeutic products to ... Read more

April 13, 2017April 13, 2017

EIU Report Urges More Government Action in Europe, Canada for People Living with Psoriasis

News

Since 2014, governments around the world have not done enough to improve the care of people living with psoriasis, says a new report issued by the Economist Intelligence Unit (EIU). Pharmaceutical giant Eli ... Read more

April 11, 2017

Cannabinoid-Based Topical Cream for Psoriasis Receiving Interest from Scientific Community

News

A cannabinoid-based topical cream to treat psoriasis is receiving interest from the global scientific and medical communities, according to the developer of the cream, One World Cannabis (OWC) Pharmaceutical Research company. ... Read more

April 6, 2017April 6, 2017

Filgotinib in Phase 2 Trials for Psoriatic Arthritis, Sjogren’s Syndrome and Ankylosing Spondylitis

News

Galapagos has initiated three Phase 2 clinical trials to evaluate filgotinib for the treatment of psoriatic arthritis, Sjogren’s syndrome, and ankylosing spondylitis. According to a press release, in psoriatic arthritis, the therapeutic ... Read more

April 4, 2017April 4, 2017

FDA Adds Fingernail Psoriasis to Prescribing Information for AbbVie’s Humira Therapy

News

The U.S. Food and Drug Administration (FDA) has approved the inclusion of fingernail psoriasis in prescribing information for Humira (adalimumab, AbbVie) a drug used by patients with moderate to severe chronic ... Read more

March 30, 2017March 30, 2017

Severe Psoriasis Affects More Men Than Women, Swedish Study Shows

News

A nationwide study in Sweden supports the long-held but unproven notion that men are more prone to developing severe psoriasis than women. The research, “Severity of Psoriasis Differs Between Men ... Read more

March 28, 2017March 28, 2017

EU Approves Amgevita for Treatment of Plaque Psoriasis, Other Inflammatory Diseases

News

The European Union has approved Amgen’s Amgevita (a biosimilar to AbbVie’s Humira, adalimumab) to treat moderate to severe chronic plaque psoriasis, as well as other inflammatory diseases. This EU approval follows a positive opinion ... Read more

March 23, 2017March 23, 2017

Novartis’ Cosentyx Eliminates Psoriasis for Up to Two Years, Clinical Trial Shows

News

Novartis’ Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis so that a patient achieves long-term, treatment-free clear skin, according to extension trial results. The trial (A2302E1) was an extension ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata